Regulus Therapeutics Inc. (RGLS)

Regulus Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Cash & Equivalents	23.83	24.29	60.45	31.09	34.12
Short-Term Investments	0	14.93	0	0	0
Cash & Cash Equivalents	23.83	39.22	60.45	31.09	34.12
Cash Growth	-39.25%	-35.11%	94.44%	-8.89%	144.86%
Receivables	0	0	0	0.5	1.14
Other Current Assets	4.35	4.86	4.79	5.14	5.15
Total Current Assets	28.18	44.08	65.24	36.73	40.41
Property, Plant & Equipment	2.54	2.58	2.85	0.73	0.92
Goodwill and Intangibles	0.03	0.06	0.08	0.13	0.27
Other Long-Term Assets	0	0	0.29	0.02	0.49
Total Long-Term Assets	2.57	2.64	3.22	0.87	1.67
Total Assets	30.75	46.72	68.45	37.6	42.08
Accounts Payable	0.2	0.18	0.29	0.54	1.32
Current Debt	1.33	4.51	0	4.65	14.63
Other Current Liabilities	6.97	6.97	4.94	6.39	5.65
Total Current Liabilities	8.51	11.66	5.23	11.58	21.6
Long-Term Debt	1.06	1.77	7.09	0	0
Other Long-Term Liabilities	0	0	1.18	0	0.47
Total Long-Term Liabilities	1.06	1.77	8.27	0	0.47
Total Liabilities	9.56	13.43	13.5	11.58	22.07
Total Debt	2.39	6.28	7.09	4.65	14.63
Debt Growth	-61.95%	-11.44%	52.41%	-68.20%	-11.73%
Retained Earnings	-513.21	-483.18	-454.85	-427.05	-411.32
Comprehensive Income	0	-0.01	0	0	0
Shareholders' Equity	21.19	33.29	54.96	26.03	20.02
Net Cash / Debt	21.44	32.94	53.36	26.44	19.49
Net Cash / Debt Growth	-34.92%	-38.26%	101.83%	35.63%	-
Net Cash Per Share	1.13	2.16	6.23	7.56	11.29
Working Capital	19.67	32.42	60.01	25.15	18.81
Book Value Per Share	1.12	2.18	6.41	7.44	11.60

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).